FOR IMMEDIATE RELEASE
HOLLISTERSTIER OFFERS COMFORT WITH NEW
MULTIPLE SKIN TESTING DEVICE
Provides 10 puncture skin tests at once with minimal patient discomfort
SPOKANE, Wash., November 9, 2007– HollisterStier’s Allergy Business Unit announced today the launch of the ComforTenTM Multiple Skin Test System, its newest allergy testing device. The device features ten surgical steel 1.2mm lancet tips, which create minimal skin trauma for comfortable allergy testing. ComforTen is the only 10-test, self-loading, surgical steel testing device on the market. ComforTen is competitively priced relative to other multiple skin test devices available today. In addition to creating a more comfortable experience for the patient; little or no trauma at the negative control site makes it easy to read skin test reactions.
Derek Constable, Ph.D., Director of New Product Discovery at HollisterStier, said, “ComforTen was developed with the Allergists, nurses, and the patients in mind. We have made every effort to create a comfortable allergy testing experience for all parties. We’re excited to introduce this new addition to the full suite of HollisterStier products.”
In addition to the device itself, the ComforTen System includes trays with three optional-use spacers (patent pending) that increase the number of tests that can be completed between fillings. “We heard allergy offices tell us they wanted a skin testing device that maximized efficiency and the ComforTen System does that,” Constable said. The trays are also supplied with self-adhesive labels allowing for customized tray labeling.
When used as directed, the ComforTen device with depth control guards will produce ten reproducible skin tests resulting in well-defined reactions. The device is equipped with directional indicators to help ensure the proper orientation and application.
About HollisterStier’s Allergy Business Unit
HollisterStier Laboratories LLC (http://www.hollisterstier.com ) is a leading Contract Manufacturer of Sterile Injectable and Lyophilization products and one of the world’s top producers of Allergenic Extracts.
It has specific manufacturing capabilities in Lyophilization, Vial Filling, Aseptic Filling and Allergenic Extracts. The company has leading pharmaceutical, generic, and biotechnology companies as its customers. The Company’s product portfolio in specialized allergenic extracts includes Mites, Venom and the Acetone PrecipitatedTM line of products; including APTM Dog. HollisterStier’s line of skin testing devices include QUINTIP®, QUINTEST®, and now ComforTenTM. HollisterStier Laboratories LLC is owned by Jubilant Organosys Ltd. (www.jubl.com ).
About Jubilant Organosys
Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceuticals value chain: from drug discovery, functional chemistry and clinical research services to custom research and manufacturing services for advance intermediates and fine chemicals, Active Pharmaceutical Ingredients and Dosage Forms.
Jubilant Organosys has geographically diversified manufacturing facilities in seven locations. Of these, five are in India and two in USA are in Salisbury, state of Maryland and Spokane, state of Washington. The Company also has subsidiaries in USA, China and Belgium. Together, these help Jubilant cater to 130 customers across more than 50 countries around the world.
The Company has 4000 employees across its locations. Jubilant is headquartered in NOIDA (state of Uttar Pradesh), India.
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.